Department of Otolaryngology-Head & Neck Surgery, AlHada Armed Forces Hospital, Taif, Saudi Arabia.
Department of Otolaryngology-Head & Neck Surgery, King Abdullah Medical City, Makkah, Saudi Arabia.
Clin Otolaryngol. 2021 Jul;46(4):720-728. doi: 10.1111/coa.13781. Epub 2021 May 6.
To carry out a meta-analysis of prospective literature comparing the clinical efficacy of elective neck dissection (END) vs observation (OBS) in patients with early-stage cT1/T2N0 tongue carcinoma.
DESIGN/SETTING/PARTICIPANTS/OUTCOME MEASURES: We systematically reviewed four databases from inception to 30-October-2020. We considered all studies meeting the following PICOS conditions: (a) Patients: early-stage cT1/T2N0 tongue carcinoma, (b) Intervention: END, (c) Comparator: OBS, (d) Outcomes: local tongue recurrence, cervical nodal recurrence, disease-specific survival (DSS) rate, and disease-free survival (DFS) rate and (e) Study design: prospective reports. We pooled dichotomous data as relative risks (RRs) with 95% confidence intervals (CIs).
Four studies (one case-control study and three randomised controlled trials) met our inclusion criteria. There were 448 eligible patients (225 and 223 patients were treated with END and OBS, respectively). END significantly correlated with improved DSS rate (RR = 1.15, 95% CI: 1.04-1.27, P = .007). Nonetheless, there were no significant differences between END and OBS groups regarding the rates of local tongue recurrence (RR = 1.23, 95% CI: 0.50-3.03, P = .65), cervical nodal recurrence (RR = 0.45, 95% CI: 0.16-1.27, P = .13) and DFS rate (RR = 1.08, 95% CI: 0.91-1.27, P = .38). Pooled analysis for cervical nodal recurrence was heterogeneous, and sensitivity analysis revealed a significantly lower cervical nodal recurrence rate in favour of END group (RR = 0.30, 95% CI: 0.13-0.67, P = .004).
END correlated with a significant decrease in cervical nodal recurrence and improved DSS rate. END might be superior to OBS in patients with early-stage cT1/T2N0 tongue cancer.
对比较早期 cT1/T2N0 舌癌选择性颈清扫术(END)与观察(OBS)临床疗效的前瞻性文献进行荟萃分析。
设计/设置/参与者/结局测量:我们系统地回顾了从成立到 2020 年 10 月 30 日的四个数据库。我们考虑了所有符合以下 PICOS 条件的研究:(a)患者:早期 cT1/T2N0 舌癌,(b)干预:END,(c)对照:OBS,(d)结局:局部舌复发、颈部淋巴结复发、疾病特异性生存率(DSS)率和无病生存率(DFS)率,以及(e)研究设计:前瞻性报告。我们将二项数据汇总为相对风险(RR)和 95%置信区间(CI)。
四项研究(一项病例对照研究和三项随机对照试验)符合纳入标准。共有 448 例合格患者(225 例和 223 例分别接受 END 和 OBS 治疗)。END 与提高 DSS 率显著相关(RR=1.15,95%CI:1.04-1.27,P=0.007)。然而,在局部舌复发率(RR=1.23,95%CI:0.50-3.03,P=0.65)、颈部淋巴结复发率(RR=0.45,95%CI:0.16-1.27,P=0.13)和 DFS 率(RR=1.08,95%CI:0.91-1.27,P=0.38)方面,END 和 OBS 组之间没有显著差异。颈部淋巴结复发的合并分析存在异质性,敏感性分析显示 END 组的颈部淋巴结复发率显著降低(RR=0.30,95%CI:0.13-0.67,P=0.004)。
END 与颈部淋巴结复发率显著降低和 DSS 率提高相关。在早期 cT1/T2N0 舌癌患者中,END 可能优于 OBS。